Phanes Therapeutics has received United States Food and Drug Administration Fast Track designation for spevatamig, its investigational CLDN18.2 and CD47-targeting bispecific antibody, for advanced and metastatic biliary tract carcinoma. The August 14, 2026 decision gives the clinical-stage biotechnology company access to an expedited development framework at a time when spevatamig is progressing through the TWINPEAK Phase 1/2 programme and Phanes is broadening its clinical strategy in biliary tract cancer.
The designation does not establish that spevatamig is effective in biliary tract cancer, nor does it mean the therapy has been approved. What it potentially changes is the efficiency of the regulatory dialogue around a programme that is becoming more ambitious. Phanes has moved the biliary tract cancer study into dose expansion and, separately, expanded its collaboration with Merck to evaluate spevatamig with pembrolizumab and chemotherapy in the first-line setting.
That combination of events makes the Fast Track decision more significant than an isolated regulatory designation. Phanes is effectively testing whether dual targeting of CLDN18.2 and CD47 can add a differentiated immunological mechanism to a treatment landscape in which checkpoint inhibitors combined with gemcitabine and cisplatin are already established first-line options. The unanswered question is whether the biological rationale will translate into sufficiently convincing biliary tract cancer data to justify larger and potentially registrational development.
What does FDA Fast Track designation actually change for the spevatamig biliary tract cancer programme?
The United States Food and Drug Administration describes Fast Track as a programme intended to facilitate development and expedite review of therapies for serious conditions where an unmet medical need may exist. A Fast Track therapy can become eligible for more frequent regulatory interactions, including discussions on development plans, clinical trial design and biomarkers, while rolling review may eventually allow portions of a marketing application to be submitted before the complete application is ready.
Those advantages can matter considerably for a bispecific antibody being developed across several tumour types because regulatory questions about dose optimisation, patient selection, combination regimens, biomarkers and the evidence needed for later-stage development can be addressed earlier. Fast Track status can also make a programme eligible for Accelerated Approval or Priority Review if the separate criteria governing those pathways are ultimately satisfied. It does not guarantee either pathway, and it does not reduce the need for adequate evidence of efficacy and safety.
Spevatamig had already received Fast Track designation in 2024 for metastatic CLDN18.2-positive pancreatic adenocarcinoma, after receiving orphan drug designation for pancreatic cancer in 2022. The new biliary tract carcinoma designation therefore expands the regulatory relevance of the programme beyond pancreatic cancer while Phanes continues to evaluate the molecule across gastrointestinal malignancies.
For Phanes, the practical opportunity is to use increased interaction with the regulator while the biliary tract cancer clinical strategy is still evolving. That could be particularly useful because the programme now spans both later-line and proposed first-line combinations rather than following one simple development route.
How far has spevatamig actually progressed in patients with biliary tract cancer?
Spevatamig is being evaluated within TWINPEAK, NCT05482893, a first-in-human Phase 1/2 open-label study examining monotherapy and combination approaches in gastrointestinal cancers including biliary tract carcinoma, pancreatic ductal adenocarcinoma, gastric cancer and gastroesophageal junction cancer. The study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy rather than serving as a completed confirmatory trial.
Phanes announced the first biliary tract carcinoma patient dosed with spevatamig plus chemotherapy in September 2025. By April 2026, the company said it had initiated dose expansion after dose-limiting toxicity clearance at two dose levels, an important development-stage step but not an efficacy conclusion. At that point, more than 160 patients had been exposed to spevatamig globally across its monotherapy and combination programmes, rather than specifically within the biliary tract cancer cohort.
The registered TWINPEAK structure provides further context. One biliary tract cancer substudy includes patients whose advanced or metastatic disease has progressed after first-line gemcitabine and cisplatin, with or without an immune checkpoint inhibitor, and who are eligible for second-line FOLFOX. That places at least part of spevatamig’s clinical evaluation in a population with an established treatment history and a substantial unmet need after first-line progression.
Importantly, Phanes has not yet disclosed the kind of mature BTC-specific response, progression-free survival or overall survival dataset that would allow the Fast Track decision to be interpreted as confirmation of clinical performance. The current regulatory milestone should therefore be viewed as support for accelerated development rather than validation of the treatment hypothesis.
Why does targeting CLDN18.2 and CD47 create a different immunotherapy proposition?
Spevatamig is an IgG-like bispecific antibody designed to engage CLDN18.2 and CD47. Phanes describes the molecule as an innate immunity enhancer and says its design is intended to promote recognition and destruction of tumour cells by macrophages and dendritic cells, creating a mechanism that could complement checkpoint inhibitors that primarily influence adaptive T-cell responses.
The CD47 component is particularly relevant because CD47 functions as an immune-evasion signal that can suppress phagocytic activity. Phanes has engineered spevatamig’s anti-CD47 arm with the objective of preferentially directing activity toward cancer cells rather than producing broad CD47 binding, an important design consideration given the challenges historically associated with targeting CD47 on normal cells. The CLDN18.2 arm is intended to provide a tumour-associated anchor for that activity.
CLDN18.2 is already an established therapeutic target in another gastrointestinal setting, with CLDN18.2-directed treatment having reached regulatory approval in gastric and gastroesophageal junction adenocarcinoma. Research has also identified CLDN18.2 expression in subsets of cholangiocarcinoma and other biliary tract tumours, supporting further clinical investigation of the target, although expression varies and the biomarker strategy remains important.
TWINPEAK consequently incorporates CLDN18.2 testing into parts of its development programme. Trial information indicates that certain expansion cohorts require tumour tissue showing CLDN18.2 expression at defined staining thresholds. That matters commercially as well as clinically because any future efficacy signal may ultimately need to be interpreted according to biomarker expression, tumour subtype and treatment setting rather than assuming that all biliary tract cancers are equally targetable.
Why is Phanes Therapeutics adding pembrolizumab when checkpoint inhibitors are already used in first-line BTC?
The competitive bar in advanced biliary tract cancer has changed significantly in recent years. The United States Food and Drug Administration approved durvalumab with gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer in September 2022, followed in October 2023 by approval of pembrolizumab with gemcitabine and cisplatin for locally advanced unresectable or metastatic disease.
Phanes is therefore not developing spevatamig against a chemotherapy-only first-line landscape. Any move into first-line BTC must contend with established chemo-immunotherapy regimens, meaning a new combination would eventually need to demonstrate a clinically meaningful reason for adding another agent to an already multi-drug treatment strategy.
That helps explain the logic behind the expanded Merck collaboration announced on July 21, 2026. The companies are now planning to evaluate spevatamig with pembrolizumab and chemotherapy in first-line biliary tract cancer, extending a clinical relationship that began in 2023. The strategy appears designed to test whether Phanes’ proposed innate immune activation can complement PD-1 checkpoint inhibition rather than compete with it as an alternative immune mechanism.
The clinical challenge is substantial. Adding a fourth biological or cytotoxic component to a treatment regimen is valuable only if incremental activity outweighs additional toxicity, logistical complexity and cost. Dose selection, treatment discontinuations, overlapping adverse events and the magnitude and durability of any efficacy improvement will therefore become increasingly important as the programme moves beyond early development.
Can Phanes use its pancreatic cancer results to strengthen the spevatamig case in biliary tract cancer?
Spevatamig’s most developed efficacy dataset currently comes from pancreatic ductal adenocarcinoma rather than biliary tract cancer. At the 2026 American Society of Clinical Oncology Annual Meeting, Phanes reported that the 2 mg/kg weekly dose of spevatamig with gemcitabine and nab-paclitaxel produced a 52.4% objective response rate and 90.5% disease control rate in its first-line metastatic pancreatic cancer cohort. The company also reported median progression-free survival of 7.3 months and median overall survival of 14.7 months among United States patients at that dose, while stating that data from a higher 3 mg/kg dose remained immature.
Those results are useful because they provide human evidence that spevatamig can be administered with standard chemotherapy and can generate antitumour activity in another difficult gastrointestinal malignancy. They also provide a broader safety database for the molecule, with Phanes reporting exposure across more than 190 patients by the time of the May 2026 pancreatic cancer update.
They cannot, however, be used as evidence that spevatamig will produce the same results in biliary tract carcinoma. Pancreatic ductal adenocarcinoma and biliary tract cancers differ biologically, clinically and in their treatment landscapes, while response rates from a non-randomised Phase 2 cohort cannot establish superiority over results from separate pivotal trials.
The pancreatic programme is therefore best understood as platform validation at an early clinical level rather than a substitute for BTC-specific evidence. Phanes completed enrolment in the pancreatic Phase 2 programme in June 2026 and expects topline results by the end of 2026, creating another potentially important readout for spevatamig while the biliary tract programme develops.
What must spevatamig demonstrate before Fast Track can become a meaningful regulatory advantage?
The next phase of the spevatamig story will depend less on the designation itself and more on what Phanes can place behind it. Dose expansion needs to establish a credible combination dose and safety profile in biliary tract cancer, while efficacy assessment will need to determine whether responses are sufficiently frequent, durable and clinically meaningful to justify continued development.
Patient selection may become equally important. If activity correlates strongly with CLDN18.2 expression, Phanes will need a reproducible biomarker strategy capable of identifying patients most likely to benefit. If activity is seen across broader levels of expression, that could potentially enlarge the development opportunity, but such a conclusion will require clinical evidence rather than mechanistic expectation.
The first-line strategy with Merck adds another layer. Because pembrolizumab plus gemcitabine and cisplatin is already an FDA-approved BTC regimen, the eventual question is not simply whether spevatamig can be combined with these agents. It is whether adding spevatamig can improve clinically important outcomes enough to warrant additional treatment burden.
Fast Track gives Phanes Therapeutics a potentially more efficient regulatory route for answering those questions, particularly through closer communication with the United States Food and Drug Administration as the clinical package develops. What it does not do is answer them in advance. Spevatamig now has regulatory momentum in a second gastrointestinal cancer setting, but the milestone that would materially change its position in biliary tract cancer remains a convincing BTC-specific clinical dataset showing that its CLDN18.2 and CD47 strategy adds measurable benefit to an increasingly competitive standard of care.
